These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34906512)

  • 1. Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity.
    Fortuno C; McGoldrick K; Pesaran T; Dolinsky J; Hoang L; Weitzel JN; Beshay V; San Leong H; James PA; Spurdle AB
    Genet Med; 2022 Mar; 24(3):673-680. PubMed ID: 34906512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suspected Germline TP53 Variants and Clonal Hematopoiesis of Indeterminate Potential: Lessons Learned From a Molecular Tumor Board.
    Xavier CB; Link R; Abreu L; Bettoni F; Marson F; Galante PAF; Masotti C; Amano MT; de Molla V; Camargo AA; Asprino PF; Sabbaga J
    Oncologist; 2023 Jul; 28(7):624-627. PubMed ID: 37159554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatic TP53 variants frequently confound germ-line testing results.
    Weitzel JN; Chao EC; Nehoray B; Van Tongeren LR; LaDuca H; Blazer KR; Slavin T; Facmg DABMD; Pesaran T; Rybak C; Solomon I; Niell-Swiller M; Dolinsky JS; Castillo D; Elliott A; Gau CL; Speare V; Jasperson K
    Genet Med; 2018 Aug; 20(8):809-816. PubMed ID: 29189820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of
    Schwartz AN; Hyman SR; Stokes SM; Castillo D; Tung NM; Weitzel JN; Rana HQ; Garber JE
    JCO Precis Oncol; 2021 Nov; 5():1677-1686. PubMed ID: 34994652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal Hematopoiesis and Mosaicism Revealed by a Multi-Tissue Analysis of Constitutional TP53 Status.
    Castillo D; Yuan TA; Nehoray B; Cervantes A; Tsang KK; Yang K; Sand SR; Mokhnatkin J; Herzog J; Slavin TP; Hyman S; Schwartz A; Ebert BL; Amos CI; Garber JE; Weitzel JN
    Cancer Epidemiol Biomarkers Prev; 2022 Aug; 31(8):1621-1629. PubMed ID: 35654360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
    Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
    JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 Variant in the Blood of a Patient with Gastric Cancer Undergoing Tumor Profiling Tests Diagnosed as Clonal Hematopoiesis.
    Kawai M; Iijima-Yamashita Y; Taguchi I; Kataoka M; Sanada M; Murakami Y; Kitagawa C; Hattori H
    Am J Case Rep; 2022 Jun; 23():e936455. PubMed ID: 35700150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants.
    Fortuno C; Lee K; Olivier M; Pesaran T; Mai PL; de Andrade KC; Attardi LD; Crowley S; Evans DG; Feng BJ; Foreman AKM; Frone MN; Huether R; James PA; McGoldrick K; Mester J; Seifert BA; Slavin TP; Witkowski L; Zhang L; Plon SE; Spurdle AB; Savage SA;
    Hum Mutat; 2021 Mar; 42(3):223-236. PubMed ID: 33300245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical management of TP53 mosaic variants found on germline genetic testing.
    Ward A; Farengo-Clark D; McKenna DB; Safonov A; Good M; Le A; Kessler L; Shah PD; Bradbury AR; Domchek SM; Nathanson KL; Powers J; Maxwell KN
    Cancer Genet; 2024 Jun; 284-285():43-47. PubMed ID: 38677009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trial.
    Weber-Lassalle K; Harter P; Hauke J; Ernst C; Kommoss S; Marmé F; Weber-Lassalle N; Prieske K; Dietrich D; Borde J; Pohl-Rescigno E; Reuss A; Ataseven B; Engel C; Stingl JC; Schmutzler RK; Hahnen E
    Hum Mutat; 2018 Dec; 39(12):2040-2046. PubMed ID: 30216591
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
    Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
    Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
    Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of germline TP53 variant classification in children with cancer.
    Tallis E; Scollon S; Ritter DI; Plon SE
    Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
    Fortuno C; Mester J; Pesaran T; Weitzel JN; Dolinsky J; Yussuf A; McGoldrick K; Garber JE; Savage SA; Khincha PP; Gareth Evans D; Achatz MI; Nichols KE; Maxwell KN; Schiffman JD; Sandoval R; ; James PA; Spurdle AB
    Hum Mutat; 2020 Sep; 41(9):1555-1562. PubMed ID: 32485079
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
    de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
    HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance.
    Berry DK; Gillis N; Padron E; Moore C; Barton LV; Gewandter KR; Haskins CG; Knepper TC
    J Genet Couns; 2024 Aug; 33(4):916-926. PubMed ID: 37715966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An updated quantitative model to classify missense variants in the TP53 gene: A novel multifactorial strategy.
    Fortuno C; Pesaran T; Dolinsky J; Yussuf A; McGoldrick K; Tavtigian SV; Goldgar D; Spurdle AB; James PA
    Hum Mutat; 2021 Oct; 42(10):1351-1361. PubMed ID: 34273903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
    Batalini F; Peacock EG; Stobie L; Robertson A; Garber J; Weitzel JN; Tung NM
    Breast Cancer Res; 2019 Sep; 21(1):107. PubMed ID: 31533767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer patients suggestive of Li-Fraumeni syndrome: mutational spectrum, candidate genes, and unexplained heredity.
    Penkert J; Schmidt G; Hofmann W; Schubert S; Schieck M; Auber B; Ripperger T; Hackmann K; Sturm M; Prokisch H; Hille-Betz U; Mark D; Illig T; Schlegelberger B; Steinemann D
    Breast Cancer Res; 2018 Aug; 20(1):87. PubMed ID: 30086788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current review of TP53 pathogenic germline variants in breast cancer patients outside Li-Fraumeni syndrome.
    Fortuno C; James PA; Spurdle AB
    Hum Mutat; 2018 Dec; 39(12):1764-1773. PubMed ID: 30240537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.